Introduction {#Sec1}
============

The International Committee of Radiological Protection (ICRP) recommended three fundamental principles (justification, optimization of protection, and application of dose limits) for radiation protection. It should be noted that with regard to medical exposure of patients, it is not appropriate to apply dose limits or dose constraints, because such limits would often do more harm than good \[[@CR1], [@CR2]\]. Therefore, the justification and optimization of protection are very important in clinical practice. However, with the development of radiation medical technology increases in the medical exposure dose are of concern. The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and the ICRP and the International Atomic Energy Agency (IAEA) recommended establishing diagnostic reference levels (DRLs) as tools for dose optimization \[[@CR3], [@CR4]\]. In Europe, the European Union (EU) required establishment of DRLs by Council Directive 97/43/Euratom in 1996 \[[@CR5]\]. It is suggested that DRLs should be set by countries, regions, academic societies or associations and they have been defined in Europe and North America \[[@CR6]--[@CR12]\]. On the other hand, in Japan the Japanese Society of Nuclear Medicine (JSNM) or other research groups have recommended the standard administration radioactivity dose \[[@CR13], [@CR14]\]. The Japan Association of Radiological Technologists (JART) recommended the reduction target dose \[[@CR15], [@CR16]\] and the JART conducted a nationwide survey of radiopharmaceutical doses \[[@CR17]\]. Unfortunately this survey was not strictly limited to "actual" administered doses but included radioactivity doses determined by the time and date of assay of radiopharmaceuticals. Until 2015, neither a nationwide survey of "actual" administered doses had been conducted nor had DRLs been proposed by any nuclear medicine-related societies or organizations.

Concerning pediatric nuclear medicine, the European Association of Nuclear Medicine (EANM) dosage card has been proposed and developed by the Pediatric Task Group EANM in Europe \[[@CR18]--[@CR21]\] and consensus guidelines have been proposed and developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in North America \[[@CR22]--[@CR26]\]. In 2014, the Japanese consensus guidelines for pediatric nuclear medicine were provided by JSNM in Japan \[[@CR27]\].

The Japan Network for Research and Information on Medical Exposures (J-RIME) was established in 2010 with the cooperation of related academic societies \[[@CR28]\]. The J-RIME decided to establish the first DRLs (Japan DRLs) of common modality as all medical radiation-related societies and organizations at the annual meeting held in 2013. Therefore, the establishment of DRLs based on the latest survey results was required by nuclear medicine-related societies and organizations. This survey was performed voluntarily by medical radiation-related societies and organizations but was not forced by national offices.

The JSNM and JSNMT conducted a nationwide survey on the actual administered radioactivity in adults for the purpose of establishing DRL in nuclear medicine.

In Japan there is a unique system for delivered radiopharmaceuticals. When radiopharmaceuticals are provided from radiopharmaceutical manufacturers to nuclear medicine facilities, the radioactivity dose has been determined by the time and date of assay of radiopharmaceuticals. For example, in the case of ^99m^Tc and ^123^I agents, the radiopharmaceutical to be delivered to the nuclear medicine facility has been assayed as the assay radioactivity (radioactivity at 12 am) of the delivery date (examination date). In addition, in the case of ^201^Tl and ^67^Ga agents, radioactivity in the two days after the delivery date is delivered (radioactivity at the delivery day is about 1.6 times the assay radioactivity). That is, the assay radioactivity does not actually mean the true administered radioactivity.

Methods {#Sec2}
=======

Distribution, collection, and contents of the questionnaire {#Sec3}
-----------------------------------------------------------

A nationwide survey on the actual administered radioactivity of adults for the purpose of providing DRLs in nuclear medicine was conducted from November 25, 2014 to January 16, 2015. The questionnaire was sent to all 1249 facilities where nuclear medicine examinations are performed in Japan, and the responses were sent to a website.

The questionnaire included items such as the average administered radioactivity dose of an adult for each diagnostic nuclear medicine examination, number of scanners, number of staff members, number of board certified nuclear medicine physicians and nuclear medicine radiological technicians.

How to calculate or evaluate the average administered radioactivity in each facility {#Sec4}
------------------------------------------------------------------------------------

The average administered radioactivity was obtained from the responses following this questionnaire.The average value of the actually measured doses at the administered time or the average value of the assay dose that was corrected for the administered time.The average administered radioactivity per week or the average administered radioactivity of several dozen times.When the administered time is set at the facility, the average dose at that time.The target administered radioactivity.In the case of rare nuclear medicine examinations, the average administered radioactivity for several months or 1 year, or, the administered radioactivity in standard procedures.For positron emission tomography (PET), the above 2 or 3 are used as a reference. The estimated radioactivity when using an automatic injecting machine for ^18^F-FDG.

When calculating the average doses, responses that appeared clearly erroneous were excluded.

Results and discussion {#Sec5}
======================

Response rate and the distribution of administered radioactivity {#Sec6}
----------------------------------------------------------------

Replies were obtained from 516 facilities (response rate 41 %). The average, 75th, 80th and 90th percentile of each administered radioactivity are shown in Table [1](#Tab1){ref-type="table"}.Table 1Nationwide survey results and diagnostic reference levels (DRLs) in JapanProcedure and radiopharmaceuticalAverage dosage in % value of nationwide survey results (MBq)DRLs (MBq)^a^75 %80 %90 %Bone: ^99m^Tc-MDP9329621045950Bone: ^99m^Tc-HMDP9379631045950Bone marrow: ^111^I *n*-Cl125125125120Cerebral blood flow: ^99m^Tc-HM-PAO (rest or stress)763800932800Cerebral blood flow: ^99m^Tc-HM-PAO (rest and stress)1155128014641200Cerebral blood flow: ^99m^Tc-ECD (rest or stress)775800848800Cerebral blood flow: ^99m^Tc-ECD (rest and stress)1007106811301100Cerebral blood flow: ^123^I-IMP (rest or stress)200211236200Cerebral blood flow: ^123^I-IMP (rest and stress)287310340300Cerebral blood flow: Iomazenil (^123^I)193195244200Dopamine transporter: Ioflupane (^123^I)186189195190Cisternography: ^111^I *n*-DTPA63637270Thyroid imaging: ^123^I-NaI991310Thyroid imaging: ^99m^Tc-pertechnetate261370370300Parathyroid: ^201^Tl-Cl120120175120Parathyroid: ^99m^Tc-pertechnetate300370391300Parathyroid: ^99m^Tc-MIBI784824848800Lung ventilation: ^81m^Kgas185185288200Lung ventilation: ^133^Xe gas468480489480Lung perfusion: ^99m^Tc-MAA260261370260Venography: ^99m^Tc-MAA459555740500Liver and spleen: ^99m^Tc-phytate185197228200Liver function: ^99m^Tc-GSA251260261260Hepatobiliary: ^99m^Tc-PMT252260261260Liver and spleen: ^99m^Tc-Sn colloid157185185180Myocardial perfusion: ^201^Tl-Cl180180196180Myocardial perfusion: ^99m^Tc-tetrofosmin (rest or stress)831880951900Myocardial perfusion: ^99m^Tc-tetrofosmin (rest and stress)1110113012471200Myocardial perfusion: ^99m^Tc-MIBI (rest or stress)818848900900Myocardial perfusion: ^99m^Tc-MIBI (rest and stress)1110112512211200Myocardial fatty acid metabolism: ^123^I-BMIPP130130159130Cardiac sympathetic nerve imaging: ^123^I-MIBG129130130130Cardiac blood pool: ^99m^Tc-HSA93193210451000Cardiac blood pool: ^99m^Tc-HSA-D94499710451000Myocardial infarction: ^99m^Tc-PYP7509251001800Salivary gland: ^99m^Tc-pertechnetate370370466370Meckel's diverticulum: ^99m^Tc-pertechnetate466523740500Gastrointestinal bleeding: ^99m^Tc-HSA-D1036104510461040Renal imaging (static): ^99m^Tc-DMSA210230261210Renal imaging (dynamic): ^99m^Tc-MAG3390400424400Renal imaging (dynamic): 99mTc-DTPA380400502400Adrenal cortex: ^131^I-Adosterol44444444Adrenal medulla: ^131^I-MIBG40404845Adrenal medulla: ^123^I-MIBG130130170130Tumor: ^201^Tl-Cl178180180180Tumor and inflammation: ^67^Ga-citrate174174208200Lymphatic system: ^99m^Tc-HSA-D (not covered with health insurance)9289321045950Sentinel lymph node: ^99m^Tc colloid111111156120Sentinel lymph node: ^99m^Tc-phytate93105127120RI angiography: ^99m^Tc-HSA-D94398710461000Tumor: ^18^F-FDG (in-house-produced)235240260240Tumor: ^18^F-FDG (delivery)252260280240Brain: ^18^F-FDG (in-house-produced)227233248240Brain: ^18^F-FDG (delivery)255259295240^15^O-CO~2~ gas: 2D7500770081008000^15^O-O~2~ gas: 2D4500540083606000^15^O-CO gas: 2D3000300038003000^15^O-CO~2~ gas: 3D2888291029552900^15^O-O~2~ gas: 3D6600730074007000^15^O-CO gas: 3D7125750077507500Myocardial metabolism: ^18^F-FDG (in-house-produced)221223236240Myocardial metabolism: ^18^F-FDG (delivery)251258287240Myocardial perfusion: ^13^N-NH~3~718--740720^a^Adult dosage (MBq)

The 75th percentile of ^99m^Tc-MDP, ^99m^Tc-HMDP (bone scintigraphy), ^99m^Tc-HM-PAO, ^99m^Tc-ECD, ^123^I-IMP (cerebral blood flow scintigraphy), ^99m^Tc-Tetrofosmin, ^99m^Tc-MIBI, ^201^Tl-Cl (myocardial perfusion scintigraphy) and ^18^F-FDG for oncology (in-house-produced and delivery) administered radioactivity were 932, 937, 763, 775, 200, 831, 818, 180, 235 and 252, respectively.

Distribution of administered radioactivity in a representative diagnostic nuclear medicine examination {#Sec7}
------------------------------------------------------------------------------------------------------

The administered radioactivity distributions of bone scintigraphy, cerebral blood flow scintigraphy, myocardial perfusion scintigraphy for single photon emission computed tomography (SPECT) and ^18^F-fluorodeoxyglucose (FDG) tumor scintigraphy in PET are shown in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}. It should be noted that in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [6](#Fig6){ref-type="fig"} the numbers of different response facilities are adjusted.Fig. 1Bone: ^99m^Tc-HMDP and ^99m^Tc-MDP. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Numbers responding for ^99m^Tc-HMDP and ^99m^Tc-MDP were 392 and 340, respectivelyFig. 2Cerebral blood flow: ^99m^Tc-ECD and ^99m^Tc-HM-PAO. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Numbers responding for ^99m^Tc-ECD and ^99m^Tc-HM-PAO were 366 and 83, respectivelyFig. 3Cerebral blood flow: ^123^I-IMP. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Number responding was 373Fig. 4Myocardial perfusion: ^99m^Tc-Tetrofosmin and ^99m^Tc-MIBI. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Numbers responding for ^99m^Tc-Tetrofosmin and ^99m^Tc-MIBI were 220 and 190, respectivelyFig. 5Myocardial perfusion: ^201^Tl-Cl. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Number responding was 384Fig. 6Tumor: ^18^F-FDG. Note: They are arranged in decreasing order to separate the nuclear medicine facility with more from those with less radioactivity. Numbers of delivery and in-house-produced were 132 and 73, respectivelyFig. 7Tumor: ^18^F-FDG, administered activity per body weight. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Number responding was 76

Figure [1](#Fig1){ref-type="fig"} shows the administered radioactivity distribution of ^99m^Tc-methylene diphosphonate (MDP) and ^99m^Tc-Hydroxymethylene diphosphonate (HMDP). In Japan, ^99m^Tc-MDP and ^99m^Tc-HMDP have been used in bone scintigraphy as radiopharmaceuticals and there are two methods of on-site preparation of kits and ready-to-use radiopharmaceuticals. Two manufacturers have provided radiopharmaceuticals for bone scintigraphy. One has 555 and 740 MBq and the other has 370, 555, 740 and 925 MBq as assay radioactivity for one patient. For the present survey, information regarding whether kits were prepared on-site or ready-to-use radiopharmaceuticals was not obtained. The administered radioactivity distribution of ^99m^Tc-MDP and ^99m^Tc-HMDP was almost the same, and, the numbers of 740 MBq in both agents were the highest because administration of radioactivity of 555--740 MBq is recommended by the package insert, texts and guidelines as a standard administration activity in Japan. The percentages of response rates in the range of 740 MBq ± 5 % of ^99m^Tc-MDP and ^99m^Tc-HMDP were 30 and 31 %, respectively. The latter is around 930 MBq because the dose of 930 MBq corresponds to the case of administration of 740 MBq (assay activity at 12 am) at 10 am. Two radiopharmaceuticals for bone scintigraphy are recommended to be scanned from 2 to 3 h after administration. This may reflect the reality that many nuclear facilities are imaging at 1 pm after administration at 10 am using an assay radioactivity of 740 MBq (ready-to-use radiopharmaceuticals).

Figure [2](#Fig2){ref-type="fig"} shows the distribution of ^99m^Tc-hexamethylpropylene amine oxime (HM-PAO) and ^99m^Tc-ethyl cysteinate dimer (ECD). In Japan, ^99m^Tc-HM-PAO and ^99m^Tc-ECD are used for cerebral blood flow scintigraphy of ^99m^Tc agents as a radiopharmaceutical. ^99m^Tc-HM-PAO is used only by on-site preparation of kits and ^99m^Tc-ECD either by on-site preparation of kits or ready-to-use radiopharmaceuticals. The assay radioactivities of ^99m^Tc-ECD are 400 and 600 MBq for one patient. Concerning ^99m^Tc-HM-PAO, the number of the responses of 740 MBq was the highest because administration radioactivity of 370--740 MBq is recommended by the package insert, texts and guidelines as a standard administration radioactivity in Japan. For ^99m^Tc-ECD, the number of responses of around 740 MBq was the most because an administration dose of around 370--740 MBq is highest by the package insert, texts and guidelines as a standard administration dose as well as ^99m^Tc-ECD. The percentages of response rates in the range of 740 MBq ± 5 % of ^99m^Tc-HM-PAO and ^99m^Tc-ECD were 61 and 33 %, respectively.

Figure [3](#Fig3){ref-type="fig"} shows the results of the distribution of *N*-isopropyl-*p*-\[^123^I\]iodoamphetamine (IMP). In Japan, for cerebral blood flow scintigraphy ^123^I-IMP is provided by only delivery. ^123^I-IMP has more kinds of assay radioactivities than other radiopharmaceuticals. One manufacturer has 111, 148, 167, 185 and 222 MBq and another has 111, 167 and 222 MBq as assay radioactivity for one patient. In addition, for ^123^I-IMP, a wide range of administration doses of 111--222 MBq is recommended by the package insert, texts and guidelines as a standard administration dose. In particular, a wide range of administration radioactivity (37--222 MBq) is recommended in the package insert. Thus, the distribution of radioactivity of ^123^I-IMP is scattered, which may reflect the various uses to which it is put at individual facilities. The response rate in the range of 111 MBq ± 5 % of ^123^I-IMP was 7 %.

Figure [4](#Fig4){ref-type="fig"} shows the distribution of ^99m^Tc-Tetrofosmin and ^99m^Tc-hexakis-2-methoxyisobutylisonitrile (MIBI). In Japan, ^99m^Tc-Tetrofosmin and ^99m^Tc-MIBI have been used for myocardial perfusion scintigraphy as ^99m^Tc agents, and, both agents have two methods of on-site preparation of kits and ready-to-use radiopharmaceuticals. ^99m^Tc-Tetrofosmin has 296, 592 and 740 MBq and ^99m^Tc-MIBI has 370, 600 and 740 MBq for one patient as the assay radioactivity. The response of around 740 MBq was the most common because an administration dose of 370--740 MBq is recommended by the package insert, texts and guidelines as a standard administration dose. The response rates in the range of 740 MBq ± 5 % of ^99m^Tc-Tetrofosmin and ^99m^Tc-MIBI were 37 and 30 %, respectively.

Figure [5](#Fig5){ref-type="fig"} shows the distribution of ^201^Tl-Cl. In Japan, ^201^Tl-Cl for myocardial perfusion scintigraphy has been made available only by delivery. The assay radioactivities of ^201^Tl-Cl are 74, 11, 148 MBq for one patient provided by two manufacturers. The responses of 111 and 180 MBq were the most common. In Japan the manufacturers usually provide ^201^Tl-Cl to the nuclear medicine facility within 2 days before the assay date; therefore, 180 MBq corresponds to the radioactivity 2 days before the assay radioactivity 111 MBq. The administration radioactivity of around 74--111 MBq is recommended by the package insert, texts and guidelines as a standard administration activity for ^201^Tl-Cl. This study indicated that many nuclear medicine facilities administered the assay radioactivity 111 MBq for one patient in Japan (actual administered radioactivity is 180 MBq). The response rate in the range of 180 MBq ± 5 % of ^201^Tl-Cl was 43 %.

The distribution of administered radioactivity for ^18^F-FDG oncology PET is shown in Fig. [6](#Fig6){ref-type="fig"} and the responses of 185 MBq were the greatest. In Japan, nuclear medicine facilities have two methods, in-housed-produced and delivery for ^18^F-FDG oncology PET. Provided manufacture of ^18^F-FDG is one and it has an assay radioactivity of only 185 MBq for one patient. For these reasons, it is presumed that the responses of 185 MBq were diverse. The response rate in the range of 185 MBq ± 5 % of ^18^F-FDG in-housed-produced and delivery were 19 and 27 %, respectively. In addition, the administered radioactivity per body weight (MBq/kg) was also investigated (Fig. [7](#Fig7){ref-type="fig"}). However, whether in-housed-produced or delivery was not distinguished by the survey items. An administered radioactivity per body weight of 2--5 MBq/kg (three dimensional collection) is recommended by the guidelines \[[@CR29]\] and it was found that most of the facilities administered within the recommended radioactivity doses per body weight. Furthermore, the numbers of responses of 3.0, 3.7 and 4.0 MBq/kg were the highest, and the administered radioactivity dose per body weight was considered is be determined in accordance with the guidelines.

This survey reveals that many nuclear facilities determined the administered radioactivity dose according to the package insert, texts and guidelines.

Comparison with EU and North America {#Sec8}
------------------------------------

Basically DRLs are determined based on 75th percentile of the survey results. To compare the administered radioactivity between Japan and EU, a summary of Japanese and EU DRLs for diagnostic nuclear medicine is shown in Table [2](#Tab2){ref-type="table"} following a list of the EU DRLs \[[@CR9]\]. Many DRL doses of radiopharmaceuticals: bone scintigraphy (^99m^Tc-MDP and ^99m^Tc-HMDP), cerebral blood flow scintigraphy (^99m^Tc-HM-PAO) and myocardial perfusion scintigraphy (^99m^Tc-Tetrofosmin and ^99m^Tc-MIBI), etc. were within the range of the EU DRLs. Concerning ^201^Tl-Cl (myocardial perfusion scintigraphy), Japan DRL 180 MBq exceeds the range of the EU DRL (75--150 MBq). For ^99m^Tc-pertechnetate (thyroid scintigraphy), Japan DRL 300 MBq exceeded the range of the EU DRLs (75--222 MBq). However, in the ^18^F-FDG for oncology PET and ^123^I-NaI for thyroid scintigraphy, Japan DRLs were at the lowest level in the range of the EU DRLs. These variations reflect the situation of each country, and so it is not considered that Japan DRLs are particularly high as compared with those of EU. Next, the results of this study were compared with SNMMI standard administered radioactivity in representative diagnostic nuclear medicine procedures: the upper limit of SNMMI standard administration radioactivity (bone scintigraphy: 1110 MBq \[[@CR30]\], cerebral blood flow scintigraphy: 1110 MBq \[[@CR31]\], myocardial perfusion ^99m^Tc agents: 1110 MBq, ^201^Tl-Cl: 148 MBq \[[@CR32]\], ^18^F-FDG oncology PET: 740 MBq \[[@CR33]\]) following facilities were bone scintigraphy (^99m^Tc-MDP: 99.4 %, ^99m^Tc-HMDP: 99.7 %), cerebral blood flow scintigraphy (^99m^Tc-HM-PAO: 100 %, ^99m^Tc-ECD: 100 %), myocardial perfusion (^99m^Tc-Tetrofosmin: 100 %, ^99m^Tc-MIBI: 100 %, ^201^Tl-Cl: 41 %) and oncology PET (^18^F-FDG of both in-housed-produced and delivery: 100 %), respectively. Almost none of the administered radioactivity doses in Japan exceeded the upper limit of SNMMI standard administration radioactivity except for ^201^Tl-Cl for myocardial perfusion. In ^18^F-FDG for oncology PET, none of the doses at any of the facilities (100 %) exceeded the lower limit of SNMMI recommended administered radioactivity.Table 2Comparisons of diagnostic reference levels (DRLs) between European Union (EU) and JapanProcedure and radiopharmaceuticalDRLs in EU^a^ (MBq)DRLs in Japan (MBq)Most common valueRangeBone: ^99m^Tc-MDP and HMDP600500--1110950Myocardial perfusion: ^201^Tl-Cl11075--150180Myocardial perfusion: ^99m^Tc-tetrofosmin (rest or stress)1200300--1500900Myocardial perfusion: ^99m^Tc-MIBI (rest or stress)1200300--1480900Tumor: ^18^F-FDG (in-housed-produced and delivery)--200--400240Thyroid: ^99m^Tc-pertechnetate8075--222300Thyroid: ^123^I-NaI2010--3710Lung perfusion: ^99m^Tc-MAA150100--296260Renal imaging (static): ^99m^Tc-DMSA--70--183210Renal imaging (dynamic): ^99m^Tc-MAG3100100--370400Renal imaging (dynamic): ^99m^Tc-DTPA--150--540400Parathyroid: ^99m^Tc-MIBI--400--900800Cerebral blood flow: ^99m^Tc-HM-PAO (rest or stress)500500--1110800Tumor and inflammation: ^67^Ga-citrate--110--370200^a^European Commission, 2010, DDM2 project report part 2: diagnostic reference levels (DRLs) in Europe

Convergence rate of the administered radioactivity, and the role of academic societies and experts {#Sec9}
--------------------------------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the percentage of facilities that were within the range (25, 30 and 50 %) from the median of representative diagnostic nuclear medicine examinations in Japan. More than half of the facilities were within the range of 25 %. In addition, more than 90 % of the facilities were within the range of 50 %. In particular, the percentage of facilities was greater than 95 % in the range of 50 % in representative diagnostic nuclear medicine procedures except for the ^99m^Tc-Tetrofosmin (myocardial perfusion scintigraphy) and ^201^Tl-Cl (myocardial perfusion scintigraphy). Our findings indicate that the administered radioactivity for diagnostic nuclear medicine has been in convergence zones in Japan.Table 3Range from median value in this study results of representative administered radiopharmaceuticalsProcedure and radiopharmaceuticalBone: ^99m^Tc-MDPBone: ^99m^Tc-HMDPCerebral blood flow: ^99m^Tc-HM-PAOCerebral blood flow: ^99m^Tc-ECDCerebral blood flow: ^123^I-IMPMyocardial perfusion: ^99m^Tc-TetrofosminMyocardial perfusion: ^99m^Tc-MIBIMyocardial perfusion: ^201^Tl-ClTumor: ^18^F-FDG (in-house-produced)Tumor: ^18^F-FDG (delivery)

Essentially, optimization of the dose by DRL is performed at each facility, and is believed to lead to optimization in the whole country or region. However, nuclear medicine facilities have a strong tendency to adhere to the texts and guidelines in Japan. Therefore, in the optimization of radiopharmaceutical doses in Japan, a greater role of societies and organizations or experts is needed. As the finding of this study shows and the current state of Japan, to optimize radiopharmaceutical doses, Achievable Doses (ADs) \[[@CR10], [@CR12]\] might be useful, too.

Development of Japan DRLs {#Sec10}
-------------------------

Based on the results of this study, a draft of Japan DRLs was prepared by the JSNM radiological protection committee.

Subsequently, it was approved by the JSNM board of directors, board of directors of the societies and organizations that performed the collaboration investigation, J-RIME general meeting and J-RIME constituent bodies, respectively, and Japan DRLs were officially published on June 7, 2015 \[[@CR34]\].

Limitation {#Sec11}
----------

Although the actual administered radioactivity doses to a standard body weight patient were obtained, the weight of the patients was not specified. It is necessary to pay attention to determine doses for DRLs when the standard body weight is different, because it is likely that the standard weight differs between Westerners and Asians.

Conclusions {#Sec12}
===========

For the first time a nationwide survey by nuclear medicine-related societies and organizations for the development of the Japanese DRLs of nuclear medicine was conducted in Japan. This study demonstrated that the administered radioactivity in diagnostic nuclear medicine in Japan has been in the convergence zone. Nuclear medicine facilities in Japan show a strong tendency to adhere to the package insert, texts and guidelines. Furthermore, the Japan administered radioactivities were within the range of variation of the EU and the SNMMI administration radioactivities. Whether nuclear facilities can optimize the dose, or whether this is required, depends on the role of the academic societies and experts.
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